|

CAR.70/IL15-transduced CB-NK cells Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • M.D. Anderson Cancer Center1

Indications

  • Germ Cell Tumors1
  • Blastic Transformation of Chronic Myeloid Leukemia1
  • Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia1
  • T-cell Non-Hodgkin's Lymphoma/ T-cell Acute Lymphoblastic Leukmeia1
  • Myelodysplastic Syndromes (MDS)1

Houston, Texas1 trial

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

M D Anderson Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.